MA44935A1 - Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires - Google Patents
Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculairesInfo
- Publication number
- MA44935A1 MA44935A1 MA44935A MA44935A MA44935A1 MA 44935 A1 MA44935 A1 MA 44935A1 MA 44935 A MA44935 A MA 44935A MA 44935 A MA44935 A MA 44935A MA 44935 A1 MA44935 A1 MA 44935A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- eye
- alpha
- treatment
- inflammatory conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des antagonistes de l'intégrine alpha 4 et leur utilisation dans des compositions pharmaceutiques, principalement des compositions ophtalmiques administrées par voie topique. Ces compositions pharmaceutiques sont utiles pour le traitement des affections inflammatoires oculaires, par exemple la sécheresse oculaire, les uvéites non-infectieuses (par exemple, l'uvéite antérieure, postérieure, intermédiaire, la panuvéite), l'iritis, la sclérite ou la conjonctivite non-infectieux chez les animaux, et en particulier chez les mammifères, y compris chez les êtres humains.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562189813P | 2015-07-08 | 2015-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44935A1 true MA44935A1 (fr) | 2019-08-30 |
Family
ID=56373100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42016A MA42016A1 (fr) | 2015-07-08 | 2016-07-07 | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires |
MA44935A MA44935A1 (fr) | 2015-07-08 | 2018-02-08 | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42016A MA42016A1 (fr) | 2015-07-08 | 2016-07-07 | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires |
Country Status (21)
Country | Link |
---|---|
US (3) | US10413535B2 (fr) |
EP (1) | EP3319639B1 (fr) |
JP (2) | JP6752276B2 (fr) |
KR (2) | KR20220062688A (fr) |
CN (1) | CN107921136A (fr) |
AU (1) | AU2016290197B2 (fr) |
BR (1) | BR112018000112A2 (fr) |
CA (1) | CA2989522C (fr) |
CL (1) | CL2018000057A1 (fr) |
ES (1) | ES2835274T3 (fr) |
HK (1) | HK1247120A1 (fr) |
IL (2) | IL256770B (fr) |
MA (2) | MA42016A1 (fr) |
MX (1) | MX2017017163A (fr) |
MY (1) | MY187552A (fr) |
PL (1) | PL3319639T3 (fr) |
RU (1) | RU2018103940A (fr) |
TN (1) | TN2017000538A1 (fr) |
UA (1) | UA123728C2 (fr) |
WO (1) | WO2017006272A1 (fr) |
ZA (1) | ZA201708601B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11524045B2 (en) | 2017-03-09 | 2022-12-13 | Allysta Pharmaceuticals, Inc. | Peptides for dry eye disease |
EP3624773A4 (fr) * | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | Compositions ophtalmiques et leurs procédés d'utilisation |
CA3114240C (fr) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7 |
CA3115830C (fr) | 2018-10-30 | 2023-09-12 | Gilead Sciences, Inc. | Composes pour inhibition de l'integrine .alpha.4.beta.7 |
JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリンの阻害のための化合物 |
US20220119383A1 (en) | 2018-10-30 | 2022-04-21 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
WO2021021668A1 (fr) * | 2019-07-26 | 2021-02-04 | Allegro Pharmaceuticals, LLC | Peptides pour le traitement de la dégénérescence maculaire non-exsudative et d'autres troubles de l'œil |
EP4013499A1 (fr) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Composés pour l'inhibition de l'intégrine alpha 4 bêta 7 |
KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0014892D0 (en) * | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
SI2444079T1 (sl) | 2005-05-17 | 2017-05-31 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje očesnih motenj |
NZ568694A (en) * | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2016
- 2016-07-07 UA UAA201800954A patent/UA123728C2/uk unknown
- 2016-07-07 ES ES16736636T patent/ES2835274T3/es active Active
- 2016-07-07 KR KR1020227015200A patent/KR20220062688A/ko not_active Application Discontinuation
- 2016-07-07 TN TNP/2017/000538A patent/TN2017000538A1/en unknown
- 2016-07-07 PL PL16736636T patent/PL3319639T3/pl unknown
- 2016-07-07 JP JP2018520045A patent/JP6752276B2/ja not_active Expired - Fee Related
- 2016-07-07 EP EP16736636.8A patent/EP3319639B1/fr active Active
- 2016-07-07 CA CA2989522A patent/CA2989522C/fr active Active
- 2016-07-07 WO PCT/IB2016/054073 patent/WO2017006272A1/fr active Application Filing
- 2016-07-07 RU RU2018103940A patent/RU2018103940A/ru unknown
- 2016-07-07 MA MA42016A patent/MA42016A1/fr unknown
- 2016-07-07 KR KR1020187003454A patent/KR102440162B1/ko active IP Right Grant
- 2016-07-07 AU AU2016290197A patent/AU2016290197B2/en not_active Ceased
- 2016-07-07 MY MYPI2017001928A patent/MY187552A/en unknown
- 2016-07-07 US US15/742,867 patent/US10413535B2/en not_active Expired - Fee Related
- 2016-07-07 MX MX2017017163A patent/MX2017017163A/es unknown
- 2016-07-07 CN CN201680040066.0A patent/CN107921136A/zh active Pending
- 2016-07-07 BR BR112018000112-0A patent/BR112018000112A2/pt not_active Application Discontinuation
-
2017
- 2017-12-18 ZA ZA2017/08601A patent/ZA201708601B/en unknown
-
2018
- 2018-01-07 IL IL256770A patent/IL256770B/en active IP Right Grant
- 2018-01-08 CL CL2018000057A patent/CL2018000057A1/es unknown
- 2018-02-08 MA MA44935A patent/MA44935A1/fr unknown
- 2018-05-25 HK HK18106821.2A patent/HK1247120A1/zh unknown
-
2019
- 2019-09-12 US US16/569,465 patent/US10751334B2/en active Active
-
2020
- 2020-04-06 JP JP2020068158A patent/JP2020121985A/ja active Pending
- 2020-07-13 US US16/927,825 patent/US20200405703A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280827A patent/IL280827A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44935A1 (fr) | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires | |
EP4374851A3 (fr) | Composition ophtalmique pour le traitement d'une maladie de l' il sec | |
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
CL2018002924A1 (es) | Inhibidores de bromodominios | |
EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
MA41496B1 (fr) | Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
MA56226A (fr) | Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale | |
MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA41985B1 (fr) | Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
MA49148A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
EA202091127A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
MA52579A (fr) | Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie |